The Advances and Challenges in Utilizing Exosomes for Delivering Cancer Therapeutics
Open accessAbstract
OPINION article Front. Pharmacol., 16 July 2018Sec. Drugs Outcomes Research and Policies Volume 9 - 2018 | https://doi.org/10.3389/fphar.2018.00735
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Exosomes are considered to have the capability of high-efficiency loading and co-transmission of therapeutic drugs.
“As a natural liposome in the human body, exosomes are considered to have the capability of high-efficiency loading and co-transmission of therapeutic drugs [21].”
From The Therapeutic Potential and Clinical Significance of Exosomes as Carriers of Drug Delivery System (2022) · cites this paper as [21]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 20 · Cited by 59
- Authors
- Yang, M., & Wu, S. Y.
- Affiliations
- The University of Queensland (AU)
- Corresponding author
- Wu, Sherry Y.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2018-07-16
- Volume
- 9
- Pages
- 735-735
- ISSN
- 1663-9812 (ISSN-L)
- PMC
- PMC6055018
- OpenAlex
- W2808932261
- Cited by
- 59
- References
- 20
- Citations by year
- 2026: 6 · 2025: 6 · 2024: 7 · 2023: 7 · 2022: 9 · 2021: 8 · 2020: 11 · 2019: 5
- FWCI
- 2.13
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Frontiers in Pharmacology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Institute of General Medical Sciences (R35GM124708)
- Ovarian Cancer Research Fund (373307)
- Ovarian Cancer Research Foundation
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- exosomes, cancer therapeutics, drug delivery, extracellular vesicles, cancer therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
